GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy

HIV Medicine
P BossiC Katlama

Abstract

To evaluate the benefits of therapeutic drug monitoring (TDM) in association with genotypic resistance testing and expert advice to optimize therapy in multiexperienced patients infected with HIV-1. Patients with a viral load>1000 HIV-1 RNA copies/mL and an unchanged antiretroviral therapy regimen over the last 3 months were randomized into two groups: a genotypic group (G) and a geno-pharmacological group (GP). Treatment was selected by an expert committee according to genotypic resistance testing (the G and GP groups) and TDM (the GP group) at week 4. Treatment could be modified at each visit according to toxicity, poor virological response and TDM. Results of TDM were withheld from the G group until week 12. The primary endpoint of the study was the percentage of patients with viral load<200 copies/mL at week 12. A total of 134 patients were randomized in the study, with 67 in each group, and included in the intent-to-treat (ITT) analysis. At baseline, median values were as follows: viral load (log(10) copies/mL): G=4.1, GP=4.0; CD4 cell count (cells/microL): G=292, GP=294; and number of prior drugs: G=7, GP=8. The median number of resistance mutations was five in the G group [nucleoside reverse transcriptase inhibitors (NRT...Continue Reading

References

Mar 28, 1998·Journal of Chromatography. B, Biomedical Sciences and Applications·K C MarshE McDonald
Oct 1, 1998·Antiviral Research·C Scholtissek, R G Webster
Oct 31, 1998·Antimicrobial Agents and Chemotherapy·A HsuE Sun
Jul 3, 1999·Pharmacotherapy·E P AcostaC V Fletcher
Jan 25, 2002·AIDS·Cristina TuralUNKNOWN Havana Study Group
Jan 31, 2002·HIV Clinical Trials·Donato Torre, Roberto Tambini
Apr 5, 2002·Clinical Microbiology Reviews·Robert W Shafer
May 11, 2002·AIDS·John D BaxterUNKNOWN CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS
Jul 4, 2002·JAMA : the Journal of the American Medical Association·Patrick G YeniPaul A Volberding
Feb 27, 2003·Antimicrobial Agents and Chemotherapy·Jean-Baptiste Guiard-SchmidWilly Rozenbaum

❮ Previous
Next ❯

Citations

Aug 11, 2005·Current HIV/AIDS Reports·Jennifer J KiserJohn G Gerber
Jun 28, 2003·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·John G Gerber, Edward P Acosta
Sep 27, 2003·HIV Medicine·A PozniakUNKNOWN BHIVA Writing Committee BHIVA Executive Committee
Nov 17, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andrea AntinoriStephen C Piscitelli
Apr 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard E NettlesCharles Flexner
Apr 1, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David W Haas
Mar 21, 2006·AIDS Research and Human Retroviruses·F Van LethUNKNOWN 2NN Study Group
Apr 25, 2012·The Canadian Journal of Hospital Pharmacy·Alice TsengDeborah Yoong
Mar 31, 2010·Expert Opinion on Drug Safety·Xia LiuFujie Zhang
Jul 28, 2006·The Lancet Infectious Diseases·Zelalem TemesgenSandro Vento
Jul 22, 2006·Scandinavian Journal of Infectious Diseases·Vidar OrmaasenJohan N Bruun
Sep 15, 2016·Expert Review of Clinical Pharmacology·Baralee PunyawudhoKiat Ruxrungtham
Nov 10, 2018·The Cochrane Database of Systematic Reviews·Theresa AvesLawrence Mbuagbaw
Jun 17, 2006·Therapeutic Drug Monitoring·David BackSaye Khoo
May 1, 2007·Current Opinion in HIV and AIDS·Saye H KhooDavid J Back
Apr 18, 2009·Current Opinion in HIV and AIDS·Charles la Porte
Jan 17, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Caroline SolasCatherine Tamalet
Sep 6, 2007·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Brookie M BestUNKNOWN California Collaborative Treatment Group 578 Study Team
Mar 4, 2020·Expert Opinion on Drug Metabolism & Toxicology·Ahizechukwu C EkeMark Mirochnick
Sep 20, 2019·Southern African Journal of HIV Medicine·Sabina F MugusiOmary Minzi
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Tamara KredoKaren Cohen
Sep 7, 2019·Current HIV Research·Thomas MaitreLionel Piroth
Sep 14, 2011·Therapeutic Drug Monitoring·Elena López AspirozMaría José García Sánchez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.